文献速递肝病

澳大利亚乙型肝炎消除进展建模

Modeling Progress Toward Elimination of Hepatitis B in Australia.
PubMed 文献 · Hepatology · 2019-10-14

该研究构建数学模型估计澳大利亚慢性乙型肝炎(CHB)负担,纳入疫苗接种、感染阶段、肝硬化进展及死亡等。结果显示2017年约221,420人感染CHB,68%已诊断,8.7%接受治疗;按当前趋势,2030年诊断率81%、治疗率12.9%,CHB归因死亡仅降5.7%,未达消除目标。

要点

  • 2017年澳大利亚CHB感染者约221,420人,诊断率68%,治疗率8.7%。
  • 按当前趋势,2030年诊断率81%、治疗率12.9%,CHB归因死亡较2015年降5.7%。
  • 2000–2017年CHB治疗已避免约2,300例死亡。

核心结论

  • 澳大利亚未能实现CHB的地方和全球消除目标。
  • 考虑人群多样性的定期更新模型有助于衡量进展并量化所需改进。

研究设计与样本

  • 构建数学建模研究,纳入疫苗接种、感染阶段、肝硬化进展及死亡,并按移民模式、出生国患病率、原住民身份和年龄整合多样性。
  • 对模型结局进行多变量不确定性分析。

主要发现

  • 2017年澳大利亚估计有221,420名CHB感染者,其中68%已诊断,8.7%接受治疗,治疗人数不足符合条件者的三分之一。
  • 按当前趋势,诊断率2022年达71%、2030年达81%;治疗率2022年达11.2%、2030年达12.9%。
  • 2015至2030年CHB归因死亡预计减少5.7%。
  • 2000至2017年CHB治疗在澳大利亚避免了约2,300例死亡。

关键数值与推荐

  • WHO 2030年目标:诊断90%的CHB感染者,治疗80%符合条件者,归因死亡减少65%。
  • 澳大利亚2022年国家目标:诊断80%,治疗20%,死亡减少30%。

临床怎么用

  • 模型可用于评估CHB消除进展并量化所需干预改进。
  • 当前治疗 uptake 远低于 eligible 人数,需加强治疗以达目标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic hepatitis B (CHB) is a significant global health concern, and the most prevalent blood-borne virus in Australia. World Health Organization (WHO) member states have committed to global elimination, with targets to diagnose 90% of people living with CHB, treat 80% of those eligible, and reduce attributable deaths by 65% by the year 2030. Australia has committed to national targets of 80% diagnosed, 20% on treatment, and a 30% reduction in deaths by 2022. APPROACH AND RESULTS: We constructed and implemented a mathematical model to estimate the burden of CHB incorporating vaccination, phases of infection, cirrhosis progression, and mortality attributed to decompensated cirrhosis and hepatocellular carcinoma and examined the population-level impact of antiviral therapy. Diversity was integrated according to migration patterns, CHB prevalence by country of birth, Indigenous status, and age. Modelled outcomes were subjected to multivariate uncertainty analysis. Of the estimated 221,420 people living with CHB in Australia in 2017, 68% were diagnosed and 8.7% were receiving treatment (less than one-third of those estimated to be eligible). Based on current trends, the proportion of people living with CHB who have been diagnosed will reach 71% by 2022 and 81% by 2030, and treatment uptake will rise to 11.2% by 2022 and 12.9% by 2030, resulting in a 5.7% reduction in CHB-attributable deaths from 2015 to 2030. CHB treatment has prevented approximately 2,300 deaths in Australia between 2000 and 2017. CONCLUSIONS: Australia is not on track to meet local and global targets regarding CHB. Comprehensive and regularly updated modelling approaches accounting for diversity within the population are a useful tool to measure progress and impact of interventions, and quantify further improvements required to meet elimination goals.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. McCulloch K, Romero N, MacLachlan J, et al. Modeling Progress Toward Elimination of Hepatitis B in Australia. Hepatology. 2019. PMID: 31419332. doi:10.1002/hep.30899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。